Arrowhead Pharmaceuticals Inc.
ARWR
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
105.3% downsideOvervalued by 105.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.97 Billion |
|---|---|
| Enterprise Value | $11.73 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.29 |
| Outstanding Shares | 142,417,000 |
Return
| Return on Equity | -50.24% |
|---|---|
| Return on Assets | -13.27% |
| Return on Invested Capital | -10.87% |
Valuation & Multiples
| P/E Ratio | -36.87 |
|---|---|
| PEG | 27.1 |
| Price to Sales | 18.14 |
| Price to Book Ratio | 12.09 |
| Enterprise Value to Revenue | 18.85 |
| Enterprise Value to EBIT | -54.69 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 1.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5330▲ 25.78% |
|---|---|
| Total Calls | 1,600,600▼ 24.47% |
| Total Puts | 853,100▲ 46.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.22%▲ 3.39% |
|---|---|
| Total Invested | $7.57B▼ 1.68% |
| Investors Holding | 455▲ 33.00% |
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
CEO: Christopher Anzalone Relevant Senate Committees
This committee's control over taxation, trade, and entitlement spending (including Medicare drug pricing) profoundly impacts pharmaceutical companies' profitability, market access, and overall valuation.
This committee allocates federal discretionary spending, directly influencing funding for scientific research (e.g., NIH, CDC) and health agencies, which can significantly impact pharmaceutical R&D, clinical trials, and potential government purchasing programs.
This committee directly regulates the FDA (drug approval process) and the NIH (research funding), both of which are paramount to the operations, R&D, and market success of any pharmaceutical company.
This committee's oversight of intellectual property (patents) and antitrust laws is fundamentally critical to the pharmaceutical industry, which relies heavily on patent protection for its products and is subject to antitrust scrutiny for mergers and market practices.
The committee's oversight of the Intelligence Community and classified briefings, particularly on global threats and biodefense, creates significant informational asymmetry for 'biotech stocks,' a category often including pharmaceutical companies involved in drug development or vaccine production, directly impacting market perception and R&D focus.